ARS Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
SPRY$3.57+13.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue: | ||||
| Product revenue, net | $33,414 | $31,300 | $77,076 | $51,863 |
| Revenue under collaboration agreements | 1,661 | 55 | 4,207 | 2,859 |
| Revenue under supply agreements | 2,635 | 1,146 | 12,766 | 1,469 |
| Total revenue | 37,710 | 32,501 | 94,049 | 56,191 |
| Operating expenses: | ||||
| Cost of goods sold (including related party amounts of $1,711, $2,046, $4,795, and $3,400, respectively) | 10,098 | 8,191 | 29,230 | 14,269 |
| Research and development (including related party amounts of $551, $559, $1,830, and $1,804, respectively) | 18,263 | 2,751 | 27,297 | 9,738 |
| Selling, general and administrative (including related party amounts of $101, $123, $362, and $354, respectively) | 43,520 | 74,751 | 193,303 | 170,167 |
| Total operating expenses | 71,881 | 85,693 | 249,830 | 194,174 |
| Loss from operations | (34,171) | (53,192) | (155,781) | (137,983) |
| Other income (expense), net: | ||||
| Interest income | 1,136 | 2,097 | 4,709 | 8,065 |
| Interest expense (including related party amounts of $127, $3, $373, and $3, respectively) | (2,552) | (56) | (7,472) | (56) |
| Total other (expense) income, net | (1,416) | 2,041 | (2,763) | 8,009 |
| Net loss | $(35,587) | $(51,151) | (158,544) | (129,974) |
| Unrealized gains (losses) on available-for-sale securities | 36 | 39 | (229) | (227) |
| Comprehensive loss | $(35,551) | $(51,112) | $(158,773) | $(130,201) |
| Net loss per share, basic and diluted | $(0.36) | $(0.52) | $(1.59) | $(1.32) |
| Weighted-average shares outstanding used in computing net loss per share, basic and diluted | 99,685,424 | 98,807,600 | 99,432,878 | 98,412,739 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.